Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.

Sulfonylureas are metabolized mainly by the cytochrome p450 2C9 (CYP2C9) enzyme. Two CYP2C9 variants--*2 (Arg144Cys) and *3 (Ile359Leu)--are associated with reduced enzyme activity and impaired substrate metabolism. We identified 1,073 incident users of sulfonylureas in Tayside, Scotland, and assess...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Zhou, K, Donnelly, L, Burch, L, Tavendale, R, Doney, A, Leese, G, Hattersley, A, McCarthy, M, Morris, A, Lang, C, Palmer, C, Pearson, E
Materialtyp:	Journal article
Språk:	English
Publicerad:	2010

Liknande verk

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.
av: Pearson, E, et al.
Publicerad: (2007)

Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with Type 2 diabetes: A Go-DARTS study
av: Donnelly, L, et al.
Publicerad: (2011)

Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.
av: Donnelly, L, et al.
Publicerad: (2011)

TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels.
av: Kimber, C, et al.
Publicerad: (2007)

Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.
av: Zhou, K, et al.
Publicerad: (2009)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
av: Pearson, E, et al.
Publicerad: (2007)

Metformin Pharmacogenetics and SLC2A2: Genome-Wide Association Study and 2-stage replication in GoDARTS and UKPDS
av: Zhou, K, et al.
Publicerad: (2013)

Retinal vascular measures from diabetes retinal screening photographs and risk of incident dementia in type 2 diabetes: A GoDARTS study
av: Alexander S. F. Doney, et al.
Publicerad: (2022-08-01)

The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy
av: Saberi M, et al.
Publicerad: (2020-06-01)

The ATPase activities of sulfonylurea receptor 2A and sulfonylurea receptor 2B are influenced by the C-terminal 42 amino acids.
av: de Wet, H, et al.
Publicerad: (2010)

The ATPase activities of sulfonylurea receptor 2A and sulfonylurea receptor 2B are influenced by the C-terminal 42 amino acids
av: De Wet, H, et al.
Publicerad: (2010)

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
av: Pearson, E, et al.
Publicerad: (2006)

Consensus recommendations on sulfonylurea & sulfonylurea combinations in the management of Type 2 diabetes mellitus - international task force
av: Sanjay Kalra, et al.
Publicerad: (2019-01-01)

Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.
av: Palmer, C, et al.
Publicerad: (2012)

Sulfonylurea: Personalized Medicine for Type 2 Diabetes
av: You-Cheol Hwang
Publicerad: (2015-12-01)

Pharmacogenetic testing in the treatment of type 2 diabetes with sulfonylurea drugs
av: G. I. Gorodetskaya, et al.
Publicerad: (2018-02-01)

The sulfonylurea receptor.
av: Ashcroft, S, et al.
Publicerad: (1992)

Commentary on “Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: International Task Force”
av: S K Singh
Publicerad: (2018-01-01)

Synthesis of coumarin sulfonamides and sulfonylurea
av: Martin Kovác, et al.
Publicerad: (2001-10-01)

Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk.
av: Lango, H, et al.
Publicerad: (2008)

Sulfonylureas in the modern strategy of therapy of type 2 diabetes
av: Lyudmila Viktorovna Nedosugova
Publicerad: (2011-06-01)

Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus
av: Lyudmila Viktorovna Nedosugova
Publicerad: (2013-06-01)

The beta-cell sulfonylurea receptor.
av: Ashcroft, S, et al.
Publicerad: (1993)

Sulfonylureas: Asset or liability?
av: Om J Lakhani, et al.
Publicerad: (2015-01-01)

Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes.
av: McCarthy, M, et al.
Publicerad: (2008)

Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.
av: Sagen, J, et al.
Publicerad: (2004)

Monotoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas
av: A Winkler, et al.
Publicerad: (2002-07-01)

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
av: Se Hee Min, et al.
Publicerad: (2015-12-01)

Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study
av: Khaled Naja, et al.
Publicerad: (2024-09-01)

The P450 gene CYP749A16 is required for tolerance to the sulfonylurea herbicide trifloxysulfuron sodium in cotton (Gossypium hirsutum L.)
av: Gregory N. Thyssen, et al.
Publicerad: (2018-09-01)

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
av: Hanefeld, M, et al.
Publicerad: (2004)

Mutations of the same conserved glutamate residue in NBD2 of the sulfonylurea receptor 1 subunit of the KATP channel can result in either hyperinsulinism or neonatal diabetes.
av: Männikkö, R, et al.
Publicerad: (2011)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
av: Yeoree Yang, et al.
Publicerad: (2016-10-01)

Adiposity-related heterogeneity in patterns of type 2 diabetes susceptibility observed in genome-wide association data.
av: Timpson, N, et al.
Publicerad: (2009)

The place of the third generation sulfonylurea glimepiride in modern therapy of type 2 diabetes mellitus
av: L.V. Zhuravlyova, et al.
Publicerad: (2019-03-01)

Sulfonylurea and neuroprotection: The bright side of the moon
av: Nawar R Hussien, et al.
Publicerad: (2018-01-01)

Mechanisms of the glycaemic effects of sulfonylureas.
av: Ashcroft, F
Publicerad: (1996)

Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial
av: Srivanichakorn W, et al.
Publicerad: (2015-03-01)

Fine-tuned photochromic sulfonylureas for optical control of beta cell Ca2+ fluxes
av: Rückert, A-K, et al.
Publicerad: (2023)

Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
av: Alla Vsevolodovna Rudakova
Publicerad: (2011-09-01)